Show/Hide Menu

First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic programs and project advancements in our Annual Report 2016.

More Info

Engineering the medicines 
of tomorrow

Learn how MorphoSys approaches drug development.

More Info

Hematological cancers 
affect adults and children alike.

MorphoSys is developing several blood cancer programs.

More Info

Antibody drugs have transformed the way 
inflammatory and autoimmune diseases are treated today.

MorphoSys is exploring new approaches to continue this success.

More Info

Solid tumors can occur in 
several organs of the human body.

MorphoSys and its partners are working on a broad portfolio of new therapies.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

20/02/2018
MorphoSys Announces That Tremfya(R) (Guselkumab) Data Demonstrated Long-...
17/02/2018
MorphoSys and Galapagos Present Results from a Phase 1 Study with MOR106...
11/12/2017
MorphoSys Presents Clinical Data on MOR208 plus Lenalidomide in Aggressive...
05/12/2017
MorphoSys Announces That Its Licensee Janssen Has Received Approval for...
30/11/2017
MorphoSys Signs Regional License Agreement for Antibody MOR202 with I-Mab
23/11/2017
MorphoSys Announces That Its Licensee Janssen Has Received Approval for...
07/11/2017
MorphoSys Announces Third Quarter 2017 Results
02/11/2017
MorphoSys Announces Presentation of Clinical Data on Proprietary Blood...
30/10/2017
Dr. Markus Enzelberger Appointed MorphoSys's Chief Scientific Officer
23/10/2017
MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody...

February 21, 2018
Oddo Seydler German Conference
Frankfurt, Germany

conferences

Therapeutic pipeline

MorphoSys has established one of the broadest pipelines in the biopharmaceutical industry.
Pipeline

Media and investors

MorphoSys is driven by the ambition to create the most valuable pipeline of biopharmaceuticals in the industry.
Media and investors

Partnering opportunities

Collaborations are a main component of our strategy. We are open to discuss deal structures where we can contribute to the development of novel drugs in a significant way.
Partnering opportunities

Drug development capabilities

MorphoSys is dedicated to become a fully integrated biopharmaceutical company including late stage clinical development and marketing/co-promotion of its own drugs.
Drug development capabilities

Leading antibody technologies

MorphoSys has made HuCAL and its successor technology Ylanthia into reliable sources of therapeutic antibody candidates.
Leading Antibody Technologies

Proprietary program MOR208

When blood formation leads to cancer: the CD19-antibody MOR208 is currently being evaluated in ALL, CLL and NHL.
MOR208

Antibody backgrounder

Antibodies are essential to life. Today, these molecules are used as therapeutic agents for the treatment of severe diseases.
Antibody Backgrounder

Lighthouse project Gantenerumab

Is being developed by Roche for Alzheimer´s desease.
Gantenerumab